MiR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer

Endocrine-Related Cancer

Volumn 20, Issue 1, 2013, Pages 91-102

  Endo, Yumi ^a   Toyama, Tatsuya ^a   Takahashi, Satoru ^a   Yoshimoto, Nobuyasu ^a   Iwasa, Mai ^a   Asano, Tomoko ^a   Fujii, Yoshitaka ^a   Yamashita, Hiroko ^a,b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Breast cancer; Estrogen receptor; MicroRNA; MiR 1290

Indexed keywords

ESTROGEN RECEPTOR ALPHA; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; LET 7A; MESSENGER RNA; MICRORNA; MICRORNA 10B; MICRORNA 146A; MICRORNA 15A; MICRORNA 193B; MICRORNA 26A; MICRORNA 34A; MIR 10A; MIR 1290; MIR 29C; MIR 342 3P; MR 129; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER SIZE; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ARYLAMINE N-ACETYLTRANSFERASE; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; IMMUNOENZYME TECHNIQUES; ISOENZYMES; MICRORNAS; MIDDLE AGED; NEOPLASM GRADING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84874026543     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0207     Document Type: Article

References (40)

1. AdamPJ, Berry J, Loader JA, Tyson KL, Craggs G, Smith P,De Belin J, Steers G, Pezzella F, Sachsenmeir KF et al. 2003 Arylamine N-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro. Molecular Cancer Research 1 826-835.
2. Badve S & Nakshatri H 2009 Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. Journal of Clinical Pathology 62 6-12. (doi:10.1136/jcp.2008.059899)
3. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG & Nakshatri H 2007 FOXA1 expression in breast cancer - correlation with luminal subtype A and survival. Clinical Cancer Research 13 4415-4421. (doi:10.1158/1078-0432.CCR- 07-0122)
4. Baquero MT, Lostritto K, Gustavson MD, Bassi KA, Appia F, Camp RL, Molinaro AM, Harris LN & Rimm DL 2011 Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts. Breast Cancer Research 13 R85. (doi:10.1186/ bcr2937)
5. Belian E, Kurucz R, Treue D & Lage H 2010 Effect of YB-1 on the regulation of micro RNA expression in drug-sensitive and drug-resistant gastric carcinoma cells. Anticancer Research 30 629-633.
6. Bieche I, Girault I, Urbain E, Tozlu S & Lidereau R 2004 Relationship between intratumoral expression of genes coding for xenobioticmetabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor a-positive postmenopausal breast carcinoma. Breast Cancer Research 6 R252-R263. (doi:10.1186/bcr784)
7. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin SF, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO et al. 2007 MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biology 8 R214. (doi:10.1186/ gb-2007-8-10-r214)
8. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, Ellis IO, Huntsman D & Caldas C 2006 Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clinical Cancer Research 12 2468-2475. (doi:10.1158/1078-0432.CCR-05-2719)
9. Clarke R, Shajahan AN, Riggins RB, Cho Y, Crawford A, Xuan J, Wang Y, Zwart A, Nehra R & Liu MC 2009 Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 114 8-20. (doi:10.1016/j.jsbmb. 2008.12.023)
10. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG, McLean CA et al. 2010 BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. British Journal of Cancer 103 668-675. (doi:10.1038/sj.bjc.6605736)
11. Dolled-FilhartM, Ryden L, CreggerM, Jirstrom K, Harigopal M, Camp RL & Rimm DL 2006 Classification of breast cancer using genetic algorithms and tissue microarrays. Clinical Cancer Research 12 6459-6468. (doi:10.1158/1078- 0432.CCR-06-1383)
12. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E et al. 2008 Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) statuswith recurrence in the arimidex, tamoxifen, alone or in combination trial. Journal of Clinical Oncology 26 1059-1065. (doi:10.1200/JCO.2007.12.9437)
13. Esquela-Kerscher A & Slack FJ 2006 Oncomirs - microRNAs with a role in cancer. Nature Reviews. Cancer 6 259-269. (doi:10.1038/nrc1840)
14. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B & Senn HJ 2011 Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of Oncology 22 1736-1747. (doi:10.1093/annonc/mdr304)
15. Gomez BP, Riggins RB, Shajahan AN, Klimach U, Wang A, Crawford AC, Zhu Y, Zwart A, Wang M & Clarke R 2007 Human X-box binding protein-1 confers both estrogen independence and antiestrogen resistance in breast cancer cell lines. FASEB Journal 21 4013-4027. (doi:10.1096/fj.06-7990com)
16. Harvey JM, Clark GM, Osborne CK & Allred DC 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of Clinical Oncology 17 1474-1481.
17. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D & Carroll JS 2011 FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nature Genetics 43 27-33. (doi:10.1038/ng.730)
18. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M et al. 2005 MicroRNA gene expression deregulation in human breast cancer. Cancer Research 65 7065-7070. (doi:10.1158/0008-5472.CAN-05-1783)
19. Kondo N, Toyama T, Sugiura H, Fujii Y & Yamashita H 2008 miR-206 expression is down-regulated in estrogen receptor a-positive human breast cancer. Cancer Research 68 5004-5008. (doi:10.1158/0008-5472. CAN-08-0180)
20. Krol J, Loedige I & Filipowicz W 2010 The widespread regulation of microRNA biogenesis, function and decay. Nature Reviews. Genetics 11 597-610. (doi:10.1038/nrg2843)
21. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R & Haqq C 2006 Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Molecular Cancer 5 24. (doi:10.1186/1476-4598-5-24)
22. Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H & Badve S 2012 FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Research and Treatment 131 881-890. (doi:10.1007/s10549-011-1482-6)
23. O'Day E & Lal A 2010 MicroRNAs and their target gene networks in breast cancer. Breast Cancer Research 12 201. (doi:10.1186/bcr2484)
24. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z et al. 2009 Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of Clinical Oncology 27 1160-1167. (doi:10.1200/JCO.2008.18.1370)
25. Perou CM, Sorlie T, Eisen MB, van de RijnM, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al. 2000 Molecular portraits of human breast tumours. Nature 406 747-752. (doi:10.1038/35021093)
26. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR et al. 2012 Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481 389-393. (doi:10.1038/nature10730)
27. Sim E, Walters K & Boukouvala S 2008 Arylamine N-acetyltransferases: from structure to function. Drug Metabolism Reviews 40 479-510. (doi:10.1080/03602530802186603)
28. Singh R & Saini N 2012 Downregulation of BCL2 by miRNAs augments drug induced apoptosis: combined computational and experimental approach. Journal of Cell Science 125 1568-1578. (doi:10.1242/jcs. 095976)
29. Smoter M, Bodnar L, Duchnowska R, Stec R, Grala B & Szczylik C 2011 The role of tau protein in resistance to paclitaxel. Cancer Chemotherapy and Pharmacology 68 553-557. (doi:10.1007/s00280-011-1696-7)
30. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S et al. 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS 100 8418-8423. (doi:10.1073/pnas.0932692100)
31. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P, Lidereau R & Bieche I 2006 Identification of novel genes that co-cluster with estrogen receptor a in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocrine-Related Cancer 13 1109-1120. (doi:10.1677/ erc.1.01120)
32. Wakefield L, Robinson J, Long H, Ibbitt JC, Cooke S, Hurst HC & Sim E 2008 Arylamine N-acetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors. Genes, Chromosomes & Cancer 47 118-126. (doi:10.1002/gcc.20512)
33. Wulfken LM, Moritz R, Ohlmann C, Holdenrieder S, Jung V, Becker F, Herrmann E, Walgenbach-Brunagel G, von Ruecker A, Muller SC et al. 2011 MicroRNAs in renal cell carcinoma: diagnostic implications of serummiR-1233 levels. PLoS ONE 6 e25787. (doi:10.1371/journal.pone. 0025787)
34. Yamashita H, Iwase H, Toyama T & Fujii Y 2003 Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells. Oncogene 22 1638-1652. (doi:10.1038/sj.onc.1206277)
35. Yamashita H, Ando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y & Iwase H 2006 Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer. Breast Cancer 13 74-83. (doi:10.2325/jbcs.13.74)
36. Yoshimoto N, Toyama T, Takahashi S, Sugiura H, Endo Y, Iwasa M, Fujii Y & Yamashita H 2011 Distinct expressions of microRNAs that directly target estrogen receptor a in human breast cancer. Breast Cancer Research and Treatment 130 331-339. (doi:10.1007/s10549- 011-1672-2)
37. Zhang J & Ma L 2012 MicroRNA control of epithelial-mesenchymal transition and metastasis. Cancer Metastasis Reviews 31 653-662. (doi:10.1007/s10555-012-9368-6)
38. Zhang H, Li Y & Lai M 2010 The microRNA network and tumor metastasis. Oncogene 29 937-948. (doi:10.1038/onc.2009.406)
39. Zhao Y, Deng C, Wang J, Xiao J, Gatalica Z, Recker RR& Xiao GG 2011 Let-7 family miRNAs regulate estrogen receptor a signaling in estrogen receptor positive breast cancer. Breast Cancer Research and Treatment 127 69-80. (doi:10.1007/s10549-010-0972-2)
40. Zinkel S, Gross A & Yang E 2006 BCL2 family in DNA damage and cell cycle control. Cell Death and Differentiation 13 1351-1359. (doi:10.1038/sj. cdd.4401987)